KeViRx, Inc. is a preclinical stage pharmaceutical company headquartered in Charlottesville, VA. We are developing small molecules drugs that treat microvascular leakage and inflammation, pathologies that are the basis for many diseases, including cancer and respiratory disease. We are now entering IND-enabling studies for pulmonary microvascular leakage and inflammation during acute lung injury.
Our lead asset, KVX-053 has potent anti-inflammatory and immunomodulatory effects. In preclinical models, KVX-053 reduces lung injury scoring & the biomarkers of lung injury, inflammation & proinflammatory cytokine release, & immune cell infiltration into the lung. KVX-053 also improves lung function after lung injury.
Contact us for more information at info@KeViRx.com.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Charlottesville, Va 22904, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://kevirx.com
- HQ
- Charlottesville, VA
Kevirx, Inc. Questions
Kevirx, Inc.'s website is http://kevirx.com
Kevirx, Inc.'s LinkedIn profile is https://www.linkedin.com/company/kevirx
Kevirx, Inc. has
5 employees.
View email and phone details for 5
employees at Kevirx, Inc..
Kevirx, Inc.'s industry is
Biotechnology Research
Kevirx, Inc.'s top competitors are
Atlas Biotech,
Vizma Life Sciences,
Dialysis-X, Inc,
Rapid Forensic Cell Typing, Inc,
Atomic Medical Innovations, Inc.,
Orthopreserve,
Light Switch Bio,
Gisens Biotech,
Genassist,
Oncoustics.
Kevirx, Inc.'s categories are Biotechnology Research
Kevirx, Inc.'s founding year is 2016
